Omeros
About OmerosPipelineInvestorsNews


Investor Relations Home

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

 
Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$13.73
Change (%) Stock is Down 0.19 (1.36%)
Volume261,448
Data as of 07/22/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
DateTitle  
06/02/14Omeros Receives FDA Approval of Omidria™ for Use in Cataract and Other Intraocular Lens Replacement Procedures
-- Omeros to Host Conference Call Today at 4:30 p.m. ET -- SEATTLE, June 2, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative pain. The approval comes with no post-marketing commi... 
 Printer Friendly Version
05/12/14Omeros Corporation Reports First Quarter 2014 Financial Results
-- Secures Additional $50.4 Million in Cash in 1Q 2014 -- SEATTLE, May 12, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and financial results for the first quarter of 2014, which include: 1Q 2014 net loss of $16.6 million, ... 
 Printer Friendly Version
04/07/14Omeros to Present at the 13th Annual Needham Healthcare Conference
SEATTLE, April 7, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 13th Annual Needham Healthcare Conference in New York later this week.  The presentation is scheduled for Wednesday, April 9, 2014 at 3:00 p.m. ED... 
 Printer Friendly Version
04/03/14Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies
-- Phase 2 Clinical Trial Planned to Begin This Quarter -- SEATTLE, April 3, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration (FDA). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key r... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
08/12/14
Omeros Corporation at Wedbush 2014 Life Sciences Conference
LocationLe Parker Meridien
New York City, NY US
Featured Report
Download Documentation 2013 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.